In youth with type 2 diabetes inadequately controlled on metformin and/or basal insulin, once-weekly tirzepatide delivered large HbA1c reductions versus placebo, with dose-related BMI decreases.
HbA1c change from baseline to week 30; lower values indicate greater improvement.
Youth-onset type 2 diabetes has limited treatment options and is often harder to control than adult-onset disease. A therapy that improves both glycaemic control and BMI addresses two central clinical challenges in this population.
| Endpoint | Tirzepatide 5 mg | Tirzepatide 10 mg | Pooled tirzepatide | Placebo | Contrast |
|---|---|---|---|---|---|
| HbA1c change | Dose-specific value not stated in supplied brief | Dose-specific value not stated in supplied brief | −2.23 pp | +0.05 pp | ETD −2.28 pp |
| BMI change | −7.4% | −11.2% | Pooled value not stated in supplied brief | −0.4% | Dose-related BMI reduction versus placebo |
Percent change in BMI at week 30 showed larger reductions with the 10 mg dose than the 5 mg dose, while placebo changed minimally.
BMI reduction is clinically relevant in adolescent type 2 diabetes because excess adiposity contributes to insulin resistance and long-term cardiometabolic risk.
The most common adverse events were gastrointestinal and were generally mild to moderate.
Gastrointestinal adverse events decreased over time, consistent with the need for early counselling and monitoring.
Discontinuation rates were not provided in the supplied summary; clinicians should review the full trial report and prescribing information.
The study was funded by Eli Lilly and Company.
Tirzepatide appears to offer a meaningful new treatment option for adolescents with type 2 diabetes who remain inadequately controlled on metformin and/or basal insulin, with substantial improvements in glycaemic control and BMI. Interpret the strong efficacy signal alongside safety monitoring, trial-size context, and industry funding disclosure.